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Summary 
In contrast to most cytokines, interleukin 4  (II_,4) expression is restricted to T  lymphocytes, 
with the exception of mast cell lines and mast cells, as more recently demonstrated in rodents. 
Little is known, however, about the capacity of human nonlymphoid cells to produce I1,4. In 
this study we show that mature human basophils are capable of expressing I1-4 and examine 
the regulation of I1.,4 production in comparison with the lipid mediator leukotriene C4. 11-4 
was produced upon immunoglobulin E receptor (IgER) activation of basophils cultured with 
Ib3, a cytokine previously shown to prime these cells for enhanced release of inflammatory mediators. 
In some experiments, I1-3 or IgER activation alone also induced I1-4 production close to the 
detection limit. The effect of IL-3 on IgER-dependent I1,4 expression was dose and time dependent: 
maximal I1-4 production occurred between 18 and 48 h preexposure of basophils to 3-10 ng/ml 
I1.-3. IgER-induced I1.-4 synthesis and release by basophils cultured with Ib3 was rapid and complete 
after 6 h. In contrast to I1,3, other cytokines (I1,5, granulocyte/macrophage colony-stimulating 
factor, and nerve growth factor) that also prime basophils for enhanced histamine and leukotriene 
C4 release did not promote IgER-induced I1,4 synthesis. Basophils appear to secrete a "TH2- 
like" cytokine profile since no detectable I1,2 or interferon 3' was produced upon IgER activation. 
Mononuclear cells (depleted of basophils), cultured in parallel, did not release I1-4 in response 
to I1-3 and/or IgER activation, and produced approximately ten times less I1-4 than basophils 
upon nonspecific activation by phorbol ester and calcium ionophore. Thus,  human basophils 
are an important cellular source of I1-4, and may, therefore, in addition to their inflammatory 
effector functions, also regulate the differentiation of T  helper cells and B cells,  in particular 
in allergic diseases. 
I 
1-4 is an immunoregulatory cytokine with a relatively re- 
stricted action on cells of the specific immune system, in 
contrast to most other cytokines with more pleiotrophic bio- 
activities. In most systems, the effects of I1-4 are antagonized 
by IFN-%  and vice versa.  IL-4 acts on T  cells inducing T 
cell proliferation and differentiation into a TH2 phenotype 
(1), and is of particular importance for the induction of IgE 
synthesis by providing an essential signal for isotype switching 
to IgE in human B cells (2, 3). Furthermore, Ib4 has some 
inhibitory activities on monocyte function such as oxygen 
radical release and the synthesis of proinflammatory cytokines 
(4), and may be involved in the emigration of cells expressing 
very late antigen 4 (lymphocytes, eosinophils, and basophils) 
by inducing vascular cell adhesion molecule expression on 
endothelial cells (5).  Thus, the regulation of I1,4 synthesis 
appears to be a key element in the initiation and progression 
of allergic diseases. 
In contrast to proinflammatory cytokines (e.g., II.,1, TNF, 
II.-8) which are produced by many cell types including tissue 
cells, the expression of cytokines with predominantly im- 
munomodulatory bioactivities, such as II.,4, IFN-3,, and Ib2, 
is largely restricted to T cells. In rodents, Ib4 is also expressed 
(among other cytokines) by crosslinking of the immunoglob- 
ulin E receptor (IgER) 1 of immature bone marrow-derived 
mast cells and mast cell lines (6-8,  for review see reference 
9). In the human system, IgER-bearing bone marrow non-B, 
non-T cells (10) and most recently lung mast cells (10a) have 
been found capable of expressing II.-4.  However, no blood 
leukocyte type other than lymphocytes has yet been identified 
to produce I1-4. 
1 Abbreviations  used  in this paper:  odgER, anti-lgER mAb; IgER, high- 
affinity IgE receptor (FceRI); LTC4, leukotriene C4; MNC, mononuclear 
cells; NGF, nerve growth factor. 
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known to express the high-afEnity IgER (FceRI). The func- 
tion of this cell type is strongly regulated by certain cytokines, 
II.,3, Ib5, GM-CSF, and nerve growth factor (NGF). A short 
preincubation  (5-10 min) with one of these cytokines strongly 
enhances  the release of inflammatory mediators in response 
to diverse agonists (11-13).  They also prime the basophils 
to  produce leukotriene C4  (LTC4)  in response  to  several 
agonists (e.g.,  C5a, monocyte-chemotactic peptide 1,  Ib8, 
C3a, platelet-activating factor) which are otherwise inactive 
in this aspect (11-15). Thus, lymphocyte products can quali- 
tatively alter the function of these myeloid effector cells. Re- 
cently established methods for purifying this rare leukocyte 
type to near homogeneity have allowed us to examine direct 
long-term effects of cytokines on basophil functions. In par- 
ticular,  we investigated whether IgER crosslinking of ma- 
ture human basophils can induce the expression  of II:4 and 
whether  this  expression  is  under  the  control  of certain 
cytokines. 
Materials and Methods 
Reagents and Media.  The following were used: Hepes (Calbio- 
chem-Behring  Corp., La  Jolh, CA); EDTA (Fluka  AG, Buchs, Swit- 
zerland); Percoll and dextran (Pharmacia, Uppsala, Sweden); fatty 
acid-free BSA (Boehringer Mannheim, Mannheim, Germany); and 
actinomycin D and cycloheximide  (Sigma Immunochemicals, St. 
Louis, MO). ALL other reagents were of the highest purity avail- 
able. Hepes buffer contained 20 mM Hepes, 125 mM NaC1, 5 mM 
KC1, and 0.5 mM glucose. HA buffer was Hepes buffer containing 
0.25 mg/ml BSA. Culture medium was RPMI 1640 supplemented 
with 10% FCS, 25 mM Hepes, 100 U/ml penicillin, and 100/zg/ml 
streptomycin, respectively,  2 mM nonessential amino acids, and 2 
mM t-glutamine (Gibco, paisley, Scotland). 
Pre~ration of  Basophils and Mononuclear  Cells.  Blood  of  unselected 
healthy  volunteers  was anticoagulated  with 10 mM EDTA and mixed 
with 0.25 volumes  of 6% dextran in 0.9% NaC1, and erythrocytes 
were allowed to sediment at room temperature. Leukocytes  were 
pelleted by centrifugation (150 g, for 20 min at room temperature) 
and resuspended  in isotonic Percoll solution with a density of 1.065 
at '-2  x  107 cells/ml. 3 ml of cell suspension were layered  on the 
top of a discontinuous PercoLL  gradient consisting of 3 ml each of 
Percoll solutions with the densities 1.079 and 1.070 g/ml, respec- 
tively. Cells were centrifuged (400 g, for 30 rain at room tempera- 
ture) and basophil-containing  interphases  between the densities 1.079 
and 1.070 were harvested. For control experiments, the upper cell 
layers, containing lymphocytes, monocytes, and generally <0.5% 
basophils (mononuclear cells [MNC]), were harvested as well and 
used in parallel under identical experimental conditions. Basophil- 
enriched fractions (10-70% basophils) were washed twice in HA 
buffer and resuspended in 150 #1 HA buffer containing 1 mg/ml 
BSA at a cell density of 70-200  x  10  + cells/ml. Basophils were 
then further purified by negative selection using antibody-coated 
paramagnetic beads (depending on  the  composition  of con- 
taminating cell types: anti-CD4, 10-18 #1; anti-CD8, 8-15 #1; anti- 
CD19, 3-7/al; antiq2D14, 3-7 ~1; anti-CD16, 3-7/al; ~  system 
[Miltenyi Biotec, Bergisch Gladbach, Germany]) (16). Basophil  pu- 
rity, as monitored by Giemsa-stained cytospin smears, generally 
ranged between 80 and 97%, the contaminating cells consisting 
mainly of small  lymphocytes  and occasionally  few monocytes.  Since 
the degree of contamination by monocytes and lymphocytes did 
not appear to influence Ib4 production under the experimental 
conditions of this study (see results), less pure basophil prepara- 
tions of 50-80% were  also used, and the results obtained were not 
excluded from data analysis. 
Culture Conditions.  Basophil  preparations, and MNC (cultured 
in parallel for comparison), were resuspended at a cell density of 
1.0-1.5  x  106 cells/ml in culture medium, incubated in sterile 
round bottomed 96-well microtiter plates (200/~l/weLL) (Becton 
Dickinson & Co., Lincoln Park, NJ) at 37~  in a humidified at- 
mosphere with 5% CO2. Cells were exposed to the different re- 
agents (added at a 0.5-1:100 vol/vol ratio). Cell-free supematants 
were then harvested after the time indicated and stored at - 20~ 
until measurements  of  cytokine  production  by ELISA  and sulfidoleu- 
kotriene synthesis by ILIA. In some experiments, cell pellets were 
lysed with 0.5% Nonidet in the original  volume of culture medium 
and two freeze/thaw cycles after which cell debris were removed 
by high-speed centrifugafion. 
Measurement of Cytoleines and Leukotriene C4/D4/E4.  Ib4 was 
measured by ELISA as described (17, 18). Briefly,  microtiter plates 
were coated with mouse anti-hlb4 antibody 8F-12 and after incu- 
bation with samples or purified rhlL-4 plates were developed with 
the biotinylated mouse anti-hlb4 antibody 3H-4 followed  by avi- 
dine-alkaline phosphatase conjugate (Calbiochem-Behring  Corp.) 
which was revealed  byp-nitrophenylphosphate  disodium  salt (Merck, 
Darmstadt, Germany). The assay  had a sensitivity  of 30 pg/ml with 
a dynamic range of up to 3 ng/ml. In some experiments, IL-4 was 
also measured  using the kit supplied  by R&D Systems  (British Bio- 
technology Ltd., Oxford, UK) with similar results. Ib2 (R&D 
Systems) and IFN-3' (Genzyme Corp., Cambridge, MA) were mea- 
sured with ELISA kits according to the manufacturer's protocols. 
Sulfidoleukotrienes were determined in a RIA as described (13). 
CellStimuli.  rhIb3 and rhGM-CSF were a kind gift of Sandoz 
(Basel, Switzerland), and rhlb5  was  from Amgen Biologicals 
(Thousand Oaks, CA) (11). rhNGF was kindly provided  by Genen- 
tech Inc. (South San Francisco, CA) (13). Purified mAb 29C6, 
directed against the non-IgE-binding epitope of the high-affinity 
IgEK ~ chain (FceRI), was a generous gift from Drs. Hakimi and 
Chizzonite  (Hoffmann-La Rrche,  Nutley, NJ)  (19). PMA and 
ionomycin were from Sigma Immunochemicals. For all cytokines 
and stimuli, stock solutions were made in HA buffer containing 
1 mg/ml BSA and 1-2 #1 were added to cell cultures. Ionomycin 
and PMA were solved in  DMSO  (final DMSO  concentration 
Results 
Mature Human Basophils Produce 11,4.  Fig. 1 demonstrates 
that purified basophils cultured during 18 h with Ib3 pro- 
duced II.-4 to variable degrees in response to IgER crosslinking 
in all experiments performed. No spontaneous Ib4 produc- 
tion was detected. In some experiments, IL-4 was also pro- 
duced in amounts dose to the detection limit of the assay 
after exposure to IL-3 alone or, less frequently, by IgER stim- 
ulation of unprimed cells. IgER-dependent Ib4 production 
by Ib3 primed cells was not affected by the percentage of 
contaminating cells within the basophil preparations since 
no correlation was found between basophii purity and IL-4 
production  (percent  basophils  vs.  pg  Ib4/106  basophils, 
r  2 --  0.047).  Furthermore, in four experiments with highly 
purified basophil preparations (90-97%) IL-4 production was 
252  _+  24 (mean  +  SEM) pg/106  basophils in response to 
606  IL-4 Production  by Human Basophils sequential exposure to IL-3 and anti-IgER mAb (c~IgER). 
Mononuclear cells from the same donors that were cultured 
under identical conditions did not release detectable amounts 
of IL-4 (data not shown). LTC4 released into the superna- 
tants was measured in parallel.  As shown in Fig.  1, LTC4 
formation in response to IgER crosslinking was also strongly 
enhanced (mean =  6.7 times more) by culturing the basophils 
overnight with IL-3. LTC4 in supernatants of unstimulated 
basophils or cells cultured with II.,3 alone was generally not 
detectable or minimal. I1.-4 release under all experimental con- 
ditions, as well as the enhancement of leukotriene synthesis 
by IL-3, but not LTC4 synthesis induced by IgER crosslinking 
alone, was abolished by treating the cells with 0.1/~g/ml 
actinomycin D or 0.1/~g/ml cycloheximide (data not shown). 
The culture time needed for Ib3 to promote IgER-dependent 
Ib4 expression was examined by varying the time intervals 
between Ib3 and odgER addition from 10 min to 65 h. These 
experiments showed that a minimum of 9 h  culture with 
II-,3 was needed for detectable Ib4 release (data not shown). 
The Ib3  effect became optimal between 18 and 41 h  (199 
_+  10  and  291  +  65  pg  IL-4/106 basophils  after  18  and 
41  h,  respectively; mean  _+  SEM,  n  =  8). 
Dose Response  for Priming and Triggering Human Basophils 
to Express I/.,4.  Fig. 2 demonstrates that ]I,3 primes basophils 
to secrete Ib4 in a dose-dependent manner. Consistent with 
Fig. 1, zero to minimal amounts of IL-4 were detected after 
stimulation with czlgER alone. Only very low concentra- 
tions of Ib3 (1-3 ng/ml) were needed to allow optimal IgER- 
dependent IL-4 production.  The enhancement of c~IgER- 
induced LTC4 synthesis after overnight culture was also dose 
dependent, occurring over a similar concentration range of 
Ib3  (Fig.  2).  In another set of experiments, variable doses 
of cxlgER mAb were used to trigger basophils cultured during 
18 h without or with a constant amount of IL-3. Again, de 
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Figure  1.  Mature human basophils produce  Ib4: donor variability of 
Ib4 and LTC4 synthesis. Purified human basophils were preincubated  for 
18 h with medium alone  or with 50 ng/ml lb3, and  then exposed to 
buffer control or to 250 ng/ml odgER mAb for 6 h. II,-4 (top) and LTC4 
(bottom) were measured in culture supernatants. Each data point represents 
the mean value of duplicates.  The results of 18 experiments  using cells 
isolated from different unselected  donors  are shown.  Bars, mean values 
of all data. 
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Figure  2.  Dose response of the Ib3 effect upon IL-4 synthesis and leu- 
kotriene  C4 generation.  Basophils (0) or MNC controls  (￿9  were cul- 
tured for 18 h with variable concentrations  of Ib3 and subsequently stimu- 
lated with 250 ng/ml algER mAb for 6 h more. (Unfilled symbols) LTC4 
generation;  (filled symbols) Ib4 synthesis. Mean values  +  SEM of three 
different experiments  performed  in duplicates. No IL-4 or LTC4 was de- 
tected in the supernatants  of basophils treated  with Ib3 alone over the 
concentration  0.1-100  ng/ml. 
novo synthesis of lipid mediators and production of IL-4 oc- 
curred dose-dependently over an identical concentration range 
of o~IgER for both basophil effector functions (Fig.  3).  In 
these experiments, low levels of IL-4 expression were also de- 
tected after exposure to IL-3 alone, however in the absence 
of LTC4 generation. No IL-4 release was detected in unprimed 
basophfls in response to otIgER at 0.1-1,000 ng/ml (data not 
shown). Figs. 2 and 3 also demonstrate the inability of MNC 
prepared from the same blood donors to produce IL-4 under 
these experimental conditions. 
Time Course of  crlgER-induced  II,4 Synthesis.  Fig. 4 shows 
the kinetic of czlgER-induced IL-4 production by human 
basophils. I1,4 synthesis and release by basophils cultured with 
IL-3 was very rapid and occurred within 2-6 h. No further 
increase of IL-4 release was observed between 6 and 24 h after 
odgER addition. By contrast, the kinetic of LTC4 synthesis 
(Fig. 4) and degranulation (12; data not shown) was clearly 
distinct since the release reaction of these inflammatory medi- 
ators was already complete 30 min after stimulation. These 
data indicate that IL-4 release in response to odgER is not 
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Figure  3.  Dose response  of cdgER mAb-induced [b4 production and 
leukotriene  C4 synthesis by basophils cultured with IL,3. Basophils (O) 
or MNC (￿9  were incubated for 18 h with 50 ng/ml Ib3 and then stimu- 
lated with variable concentrations  of monoclonal odgER for 6 h more. 
(Unfilled symbols)  LTC4 (ng/106 basophfls); (filled symbols)  Ib4 (pg/106 
basophils or MNC, respectively). Mean values + SEM, n -  6) are shown. 
No II~ was detected after c~IgER stimulation of basophils cultured without 
Ib3 in these experiments. 
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Figure 4.  Kinetic of algER mAb-induced II.-4 production and leu- 
kotriene C4 synthesis. Basophils (0) and control MNC (,)  were cul- 
tured for 18 h in 50 ng/ral Ib3 before exposing them to 250 ng/ml algER 
mAb. (x-axis) Time (h) after algER mAb addition. Time-point zero in- 
dicates the IL-4 production induced by Ib3 alone that was not increased 
during further incubation  (data not shown). (Filled symbols) lb4; (unfilled 
symbols) LTC4. Mean values are shown  +_  SEM, n  -  6). 
due to a release reaction of preformed and granule-stored Ib4 
that may have been synthesized during culture with IL-3. To 
further address this question, we examined IL-4 in culture 
supernatants as well as in lysed cell pellets ofbasophils treated 
with either buffer control, IL-3 or algER alone, or the se- 
quential combination of both. Cell-associated Ib4 was only 
detected in IL-3 primed basophils exposed to algER stimu- 
lation, possibly representing Ib4 in a process of  being secreted, 
but not in cell lysates under the other experimental condi- 
tions (data not shown). Furthermore, actinomycin, or cy- 
doheximide (5/zg/ml) added to Ib3 primed cells just before 
IgER stimulation strongly suppressed Ib4 release (data not 
shown). Taken together, these results indicate that IL-4 secre- 
tion in response to IgER crosslinking of Ib3 primed basophils 
is due to de novo synthesis of IL-4. 
Human Basophils  Produce  a TH2-1ike Profile  of  CWkines.  P,e- 
cent studies in vitro and ex vivo have shown that Th cells 
can  differentiate  into  subsets  with  a distinct capacity  for 
producing different cytokines, in particular with regard to 
the expression of either II.-4 or IFN-'y and Ib2, respectively 
(1, 20-22). Therefore, culture supernatants from representa- 
tive experiments shown above were tested for the presence 
of IFN-~/or Ib2.  Under none of the experimental condi- 
tions, including those resulting in I1.-4 release, did we detect 
any IFN-3~ or II.-2, whereas in culture supernatants of con- 
trol MNC stimulated with PMA/ionomycin, large amounts 
of these cytokines were measured (data  not shown). 
vn~etct of Basophil-priming  Cytokines  on IgER-induced  11-.4 
/on.  Apart from IL,3, two other hematopoietic growth 
factors, Ib5 and GM-CSF, as well as the neurotrophic cytokines 
NGF have been shown to rapidly modify basophil mediator 
release in a way similar to Ib3. These cytokines were there- 
fore tested for their ability to promote IgER-induced Ib4 
production. Basophils were cultured overnight with these 
cytokines at concentrations maximally effective with regard 
to their priming activity for basophil mediator release, and 
then stimulated by IgER cross[inking for 6 h. Ib4 produc- 
tion was measured and compared with that of Ib3-treated 
basophils.  Fig.  5 shows that Ib3 strongly primes basophils 
Figure 5.  Effect  of other cytokines capable of enhancing basophil medi- 
ator release  upon algER mAb-induced  Ib4 synthesis. Basophils were cul- 
tured for 18 h in medium alone or with Ib3 (50 ng/ml), IL-5  (30 ng/ml), 
GM-CSF (50 ng/ml), or NGF (30 ng/ml), before exposure to buffer con- 
trol (O) or to algER mAb (250 ng/ml) for 6 h more. Mean values of 
three different experiments are shown. Bars, SD. (  ....  ) Detection limit 
of the assay. 
for IgER-induced Ib4 synthesis, whereas IL-5 and GM-CSF, 
as well as NGF were absolutely inactive  in this respect. 
Comparison of the Capacity  to Produce 11.,4 in Response to 
Nonspeci.fic Activation between Human Peripheral  Blood Basophils 
and MNC.  Since lymphocytes are a well-estabhshed source 
of Ib4, it was interesting to compare the general capacity 
of basophils and MNC to produce IL-4. Basophils,  as well 
as  MNC  consisting of lymphocytes and  monocytes and 
depleted of basophils (<0.5%), purified from the same blood 
specimens of different  donors, were stimulated with PMA 
and ionomycin, a combination known to be a particular po- 
tent mode to induce cytokine expression in most cell types. 
Under these conditions, basophils produced Ib4 in amounts 
dearly exceeding that induced by IgER cross[inking of II.-3 
primed basophils. It is striking that basophils produced nearly 
one order of magnitude more IIA than MNC under iden- 
tical conditions, further emphasizing that basophils may rep- 
resent a particularly important source of Ib4 among different 
Figure 6.  Comparison of the capacity to produce IL-4  between basophils 
and MNC. Basophils and MNC, isolated from the same blood specimen 
of different donors were stimulated for 24 h with a combination  of PMA 
(5 ng/ml) and ionomycin (1/~M) and lb4 released in the supernatant was 
measured. Mean values  _+  SD of four experiments performed in dupli- 
cates are shown. 
608  lb4 Production  by Human Basophils blood leukocyte types (Fig. 6). Furthermore, stimulation of 
basophils with ionomycin alone resulted in II,4 production 
as well, comparable to that induced by sequential stimula- 
tion by IL-3 and odgER, whereas that produced by MNC 
was low and close to the detection limit (data not shown). 
Diacuuion 
Basophils  are  an  important  source  of  vasoactive  and 
proinflammatory mediators that are released from granule 
stores  (e.g.,  histamine) or de novo synthesized (e.g.,  leu- 
kotrienes) upon stimulation with IgE-dependent or -indepen- 
dent agonists. This study shows that mature human periph- 
eral blood basophils cultured with IL-3 are also capable of 
producing substantial amounts of IL-4 upon crosslinking of 
the high-at~nity IgER. Although basophil preparations were 
not purified to 100% homogeneity, several lines of evidence 
indicate that indeed mature basophils were the source of Ib4 
released  under the experimental conditions of this study. 
Basophils are the only PBL known to express the high-affinity 
IgER, and lb4 was produced in response to stimulation with 
a mAb specific to the c~ chain of the FceRI. IgER-dependent 
IL-4 production was only observed in Perco11 fractions en- 
riched in basophils, independent of the degree of contamina- 
tion with leukocyte types other than basophils,  and never 
in MNC depleted of basophils. Although we cannot exclude 
the existence of IgER-bearing nongranulated "non-B, non-T 
cells" in the peripheral blood capable of producing IL-4, such 
cells would be expected to accumulate in the PercoLl  fraction 
of lower density rather than in the fraction containing granu- 
lated basophils.  Mature human basophils consistently pro- 
duced Ib4 after culture with IL-3 for 18-42 h upon cross- 
linking of the IgER.  In some experiments, Ib4 was also 
detected in supernatants of cells cultured with either Ib3, 
and less frequently, with odgER alone, possibly because both 
ligands by themselves can induce low levels of IL-4 expres- 
sion near the detection limit of the assay. Alternatively, cells 
of certain individuals may need only one of the two signals. 
Ib3 primed the human basophils for IgER-dependent Ib4 
synthesis dose-dependently at  low concentrations (0.1-10 
ng/ml). This dose range is similar to that previously found 
to enhance basophil mediator release and prime the cells for 
LTC4 synthesis in response to appropriate agonists (11, 12). 
Two other hematopoietic growth factors, GM-CSF and Ib5, 
as well as a neurotrophic cytokine, NGF, have been found 
capable of rapidly modifying the basophil response in an iden- 
tical manner to Ib3 with regard to histamine release and leu- 
kotriene generation (11-13).  Basophils  carry  high-a~nity 
receptors for Ib3, IL-5, and GM-CSF with variable degrees 
of competition of binding among these three growth factors 
(23,  and our own unpublished results),  due to a common 
high-affinity converter/signal transducer (KH97/gp120) re- 
ceptor/3 chain for IL-3, Ib5,  and GM-CSF (24,  25).  It is 
interesting that only ceils cultured with Ib3, but not with 
GM-CSF, IL-5, or NGF, were able to synthesize and release 
Ib4 in response to IgER crosslinking. This difference in the 
cytokine profile capable of rapidly priming basophils for LTC4 
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synthesis on the one hand, and priming the calls for Ib4 
production after prolonged culture on the other, suggests that 
in addition to the common/3 chain, the cytokine-specific o~ 
chain may also participate in signal transduction for these 
hematopoietic growth factors, particularly regarding the later 
occurring downstream events regulating gene expression. Al- 
ternatively,  basophil priming for II.,4 synthesis may require 
a critical amount of occupied receptors, higher than that neces- 
sary for enhancing the release of inflammatory mediators, and 
thus the unique property of IL-3 may be due to different 
receptor densities for these hematopoietic growth factors (23). 
The fact that 11,3, apart t~om potentiating basophil mediator 
release, also regulates the expression of the immunomodula- 
tory cytokine IL,4 in this cell type, suggests that Ib3 may 
have an important function in the pathogenesis of immediate- 
type hypersensitivity diseases. Indeed, recent in situ hybrid- 
ization studies of allergic late-phase reactions show that IL-3 
is expressed possibly by activated TH2 helper cells (26). Fur- 
thermore, eosinophils have been shown to express, at least 
upon calcium ionophore stimulation, hematopoietic growth 
factors (e.g., II.-3, Ib5, GM-CSF) which may act in an auto- 
crine manner (27, 28). The capacity of eosinophils to express 
Ib3 that regulates basophil functions may also represent a 
link of interaction between these effector cell types in allergic 
inflammatory exudates. 
The regulation of Ib4 expression in human basophils was 
not investigated in detail. Our data indicate that IgER acti- 
vation of Ib3 primed basophils  induces the release of Ib4 
by de novo synthesis. It is unlikely that Ib3 by itself induces 
the synthesis of Ib4 that is stored in the cell granules and 
released upon receptor stimulation. Cell-associated IL-4 was 
detected only in IL-3 primed cells after IgER crosslinking, 
presumably representing the fraction of IL-4 in the process 
of being secreted, but not in basophils exposed to Ib3 alone, 
and the protein synthesis inhibitor cycloheximide or the RNA 
synthesis inhibitor actinomycin, added after IL-3 culture and 
just before IgER stimulation abolished Ib4 release without 
affecting leukotriene synthesis. However, it is unclear whether 
Ib3 and odgER act synergistically  by an identical mecha- 
nism on transcription, RNA stability and/or translation, or 
whether these events are regulated separately by these two 
signals. 
IgER-induced Ib4 production by Ib3 primed basophils 
occurred rapidly and was completed within 6 h. IL-4 release 
was, however, clearly slower and distinct from the very rapid 
degranulation response and synthesis of LTC4, further dis- 
sociating these cellular responses. The amount of Ib4 pro- 
duced by basophil within 6 h after IgER. stimulation was 
comparable to that produced by PHA-activated MNC within 
24 h (our unpublished observations).  It is also interesting 
to note that activation ofbasophils by a combination ofphorbol 
ester and calcium ionophore, a particularly potent mode of 
cytokine expression in most cell types, results in a consider- 
ably higher II:4 release than stimulation of the MNC frac- 
tion under identical conditions, further emphasizing the high 
potential of human basophils  to express I1.-4. 
Whereas most cytokines can be produced by many different 
cell types,  the expression of IL-4, Ib2, and IFN-3~ is more restricted to the lymphocyte lineage.  In the rodent system, 
certain mast cell lines,  IL3-dependent cell lines,  and bone 
marrow-derived mast cells have been shown to express Ib4, 
among other less restricted cytokines (6-9),  mainly on the 
level of gene expression with little information about product 
release.  Even  less is  known about  the capacity of human 
mucosal and connective tissue-type mast cells to express and 
release cytokines. Skin mast cells have been shown to express 
TNF-ot (29) and a recent paper indicates that human lung 
mast cells can produce Ib4 (10a). The profile of cytokines 
regulating mediator release by human basophils and mucosal 
lung mast cells suggests that the human basophils are func- 
tionally more related to mouse mucosal mast cells than they 
are to human mucosal mast cells (30). Thus, further studies 
are needed to define the importance ofbasophils or mast cells, 
respectively,  as a  source  of Ib4  or other cytokines in the 
human system. 
An increasing number of studies,  including our own, in- 
dicate that the cells of the adaptive immune system strongly 
regulate the effector functions of granulocytic cells of the in- 
nate immune system in an antigen-independent  manner by the 
release of different cytokine profiles (e.g.,  Ib3, II.-5 of TH2 
cells regulating eosinophil and basophil functions). On the 
other hand, recent studies indicate that myeloid inflamma- 
tory effector cells can express several cytokines as well, and 
may thus influence the function of the adaptive immune 
system. With regard to Ib4 expression, however, the basophil 
appears to be the only yet identified nonlymphoid leukocyte 
type capable of producing this important immunoregulatory 
cytokine. The capacity of basophils to rapidly produce Ib4, 
in the absence of detectable Ib2 and IFN-3~ expression,  indi- 
cates that this cell type, apart from its inflammatory effector 
function, also regulates the maturation and differentiation 
of T  cells (differentiation into TH2 phenotype) (1, 31) and 
B cells (IgE switch) (2). Thus, basophils may also represent 
immunomodulatory  cells involved in the propagation and pos- 
sibly even the initiation of immediate-type hypersensitivity 
disease, or also in the pathogenesis of infectious diseases with 
inadequate TH1 cell-mediated protective immunity (31). 
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